End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
179,900 KRW | -1.96% | -6.06% | -10.72% |
May. 24 | Celltrion Receives European Commission Approval of Omlyclo® (CT-P39), the First and Only Omalizumab Biosimilar Approved in Europe | CI |
May. 10 | Celltrion's Q1 Attributable Profit Slumps 86% | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.72% | 27.12B | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+43.91% | 40.65B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B | |
-8.12% | 11.19B |
- Stock Market
- Equities
- A068270 Stock
- News Celltrion, Inc.
- Celltrion's Q1 Attributable Profit Slumps 86%